Adaptimmune Therapeutics
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, founded in 2007. The company specializes in developing T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform that allows it to identify cancer targets, engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its innovative approach strengthens patient T cell responses through the use of affinity T cell receptor proteins to target and eliminate cancerous or infected cells. The company’s therapeutic programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, addressing various cancer types.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focused on developing innovative T cell receptor therapies for cancer treatment. The company's leading product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing phase I/II clinical trials for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another candidate, TC-110, targets CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 leverages extensive expertise in T cell biology to create differentiated therapies that stand apart from traditional CAR-T cell treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.